Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Tanked on Tuesday

By Eric Volkman - Feb 23, 2021 at 6:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The "other" coronavirus vaccine is currently having a moment in the spotlight.

What happened

Shares of Moderna (MRNA 0.70%) fell by almost 6% on Tuesday. While the company's mRNA-1273 remains one of only two coronavirus vaccines authorized by the Food and Drug Administration, its counterpart seems to be the one getting all the positive press lately.

So what

The yang to mRNA-1273's yin is BNT162b2 from Pfizer (PFE 3.00%) and German biotech BioNTech (BNTX 1.32%).

On the back of research indicating that the BNT162b2 vaccine can be stored for up to two weeks at lower temperatures than previously anticipated, the FDA on Tuesday approved it to be stashed in standard freezer environments. Previously, only ultra-cold storage was deemed appropriate.

Man receiving a vaccination shot.

Image source: Getty Images.

This means that the shipping and storage requirements for BNT162b2 will be much less burdensome (at the moment, due to the ultra-cold limitations, it also has to be transported in specialized containers).

Combined with other research indicating that the Pfizer/BioNTech vaccine is highly effective after just one dose, this makes BNT162b2 a much more compelling option in an environment where mass inoculations are required, and required yesterday.

Now what

But we shouldn't lose sight of the fact that Moderna's vaccine never required ultra-cold storage. Like BNT162b2, it's also been shown to be extremely effective; no wonder the U.S. government last week ordered 100 million additional doses of it.

Moderna's jab will continue to be instrumental in the fight against the coronavirus, so investors shouldn't be discouraged about the company's prospects. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$144.27 (0.70%) $1.01
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.59 (3.00%) $1.50
BioNTech SE Stock Quote
BioNTech SE
BNTX
$134.04 (1.32%) $1.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.